- Home
- IMTX vs FLGT Comparison
IMTX vs FLGT Comparison
Compare IMTX & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMTX
- FLGT
- Stock Information
- Founded
- IMTX N/A
- FLGT 2011
- Country
- IMTX Germany
- FLGT United States
- Employees
- IMTX N/A
- FLGT N/A
- Industry
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- FLGT Medical Specialities
- Sector
- IMTX Health Care
- FLGT Health Care
- Exchange
- IMTX Nasdaq
- FLGT Nasdaq
- Market Cap
- IMTX 865.5M
- FLGT 697.3M
- IPO Year
- IMTX N/A
- FLGT 2016
- Fundamental
- Price
- IMTX $9.39
- FLGT $23.01
- Analyst Decision
- IMTX Strong Buy
- FLGT Buy
- Analyst Count
- IMTX 5
- FLGT 3
- Target Price
- IMTX $15.00
- FLGT $25.33
- AVG Volume (30 Days)
- IMTX 800.4K
- FLGT 228.6K
- Earning Date
- IMTX 11-17-2025
- FLGT 11-07-2025
- Dividend Yield
- IMTX N/A
- FLGT N/A
- EPS Growth
- IMTX N/A
- FLGT N/A
- EPS
- IMTX N/A
- FLGT N/A
- Revenue
- IMTX $152,823,253.00
- FLGT $303,223,000.00
- Revenue This Year
- IMTX N/A
- FLGT $15.19
- Revenue Next Year
- IMTX N/A
- FLGT $10.58
- P/E Ratio
- IMTX N/A
- FLGT N/A
- Revenue Growth
- IMTX 83.61
- FLGT 4.31
- 52 Week Low
- IMTX $3.30
- FLGT $14.57
- 52 Week High
- IMTX $11.40
- FLGT $23.57
- Technical
- Relative Strength Index (RSI)
- IMTX 79.00
- FLGT 60.31
- Support Level
- IMTX $6.90
- FLGT $22.05
- Resistance Level
- IMTX $9.25
- FLGT $23.57
- Average True Range (ATR)
- IMTX 0.46
- FLGT 0.68
- MACD
- IMTX 0.27
- FLGT 0.02
- Stochastic Oscillator
- IMTX 95.86
- FLGT 74.94
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.